This is a double blinded randomized clinical trial of pioglitazone vs. placebo in overweight
or obese, diabetic and non-diabetic hemodialysis patients. This study will examine whether
pioglitazone modulates adipokine production by adipose tissue in hemodialysis patients and
whether these changes result in reduction of inflammation, insulin resistance and oxidative
stress and increase in muscle mass.
In addition, this study will also examine the associations of adiposity with adipokines and
the metabolic milieu in hemodialysis patients to better understand the biology of adipocytes
in uremic milieu.
Phase:
N/A
Details
Lead Sponsor:
University of Utah
Collaborators:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) University of Colorado, Denver